{'52WeekChange': 0.25794077,
 'SandP52WeekChange': None,
 'address1': '171 Oyster Point Boulevard',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 71.77,
 'askSize': 1000,
 'averageDailyVolume10Day': 486050,
 'averageVolume': 878001,
 'averageVolume10days': 486050,
 'beta': 1.879408,
 'beta3Year': None,
 'bid': 71.73,
 'bidSize': 900,
 'bookValue': 8.599,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 72.7,
 'dayLow': 70.47,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -12.943,
 'enterpriseToRevenue': 246.46,
 'enterpriseValue': 3999052544,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 67.96657,
 'fiftyTwoWeekHigh': 87.54,
 'fiftyTwoWeekLow': 39.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 53420856,
 'forwardEps': -2.51,
 'forwardPE': -28.581673,
 'fromCurrency': None,
 'fullTimeEmployees': 352,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.02479,
 'heldPercentInstitutions': 1.0183799,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/gbt.com',
 'longBusinessSummary': 'Global Blood Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in the discovery, '
                        'development, and delivery of treatments for '
                        'underserved patient communities. It is developing its '
                        'lead product candidate, Oxbryta (voxelotor) tablets, '
                        'an oral, once-daily therapy for sickle cell disease '
                        '(SCD). The company is evaluating Oxbryta that has '
                        'completed Phase III clinical trial in adult and '
                        'adolescent patients with SCD. It is also evaluating '
                        'the safety and pharmacokinetics of single and '
                        'multiple doses of Oxbryta in a Phase IIa clinical '
                        'trial of adolescent and pediatric patients with SCD. '
                        'The company has a license and collaboration agreement '
                        'with Syros Pharmaceuticals, Inc. to discover, '
                        'develop, and commercialize therapies for SCD) and '
                        'beta thalassemia. Global Blood Therapeutics, Inc. was '
                        'founded in 2011 and is headquartered in South San '
                        'Francisco, California.',
 'longName': 'Global Blood Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 4371856896,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_208736100',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -290868992,
 'nextFiscalYearEnd': 1640908800,
 'open': 71.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.43,
 'phone': '650 741 7700',
 'previousClose': 72.08,
 'priceHint': 2,
 'priceToBook': 8.342831,
 'priceToSalesTrailing12Months': 269.43527,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 72.7,
 'regularMarketDayLow': 70.47,
 'regularMarketOpen': 71.26,
 'regularMarketPreviousClose': 72.08,
 'regularMarketPrice': 71.26,
 'regularMarketVolume': 478323,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 60940300,
 'sharesPercentSharesOut': 0.1522,
 'sharesShort': 9276051,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9562369,
 'shortName': 'Global Blood Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1761,
 'shortRatio': 8.32,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'GBT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.892,
 'twoHundredDayAverage': 67.93392,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '1c0c17c6-9b4b-3d53-a36b-52e620b31c6d',
 'volume': 478323,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.gbt.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}